{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T14:36:04.887632",
  "document": "01_Article_Iptacopan C3G Trial.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 10,
  "total_validated": 10,
  "total_rejected": 0,
  "genes": [
    {
      "matched_text": "C3",
      "hgnc_symbol": "C3",
      "full_name": "complement C3",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "1318",
        "entrez": "718",
        "ensembl": "ENSG00000125730",
        "uniprot": "P01024",
        "omim": "120700"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "1318",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "718",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000125730",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "120700",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P01024",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "280133",
          "disease_name": "Complement component 3 deficiency",
          "association_type": "Disease-causing germline mutation(s) (loss of function) in"
        },
        {
          "orphacode": "544472",
          "disease_name": "Atypical hemolytic uremic syndrome with complement gene abnormality",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": ", Marina Vivarelli, Carla M Nester, Giuseppe Remuzzi, Ming-Hui Zhao, Edwin K S Wong, Yaqin Wang, Induja Krishnan, Imelda Schuhmann, Angelo J Trapani, Nicholas J A Webb, Matthias Meier, Ruben K Israni, Richard J H Smith, on behalf of APPEAR-C3G investigatorst\n\nFunding Novartis Pharma.\n\nIntroduction\n\nC3 glomerulopathy is an ultra-rare and severe form of primary chronic glomerulonephritis with an estimated\n\nOral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study @k® CrossMark\n\nBackground C3 glomerulopathy",
      "page": 1,
      "mention_count": 2,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "C5",
      "hgnc_symbol": "C5",
      "full_name": "complement C5",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "1331",
        "entrez": "727",
        "ensembl": "ENSG00000106804",
        "uniprot": "P01031",
        "omim": "120900"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "1331",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "727",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000106804",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "120900",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P01031",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "169150",
          "disease_name": "Immunodeficiency due to a late component of complement deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "ften considerable side-effects. Iptacopan is an oral complement inhibitor that targets factor B and selectively inhibits the alternative pathway by blocking C3 convertase activity and inhibiting the alternative pathway amplification loop, thus preventing downstream generation of alternative pathway C5 convertase, C3a and C5a anaphylatoxins, and the membrane attack complex. Iptacopan is also approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria and for the reduction of proteinuria in adults with primary IgA nephropathy. In a phase 2 study, 12-week iptacopan treatment resu",
      "page": 1,
      "mention_count": 2,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "kit",
      "hgnc_symbol": "KIT",
      "full_name": "KIT proto-oncogene, receptor tyrosine kinase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "6342",
        "entrez": "3815",
        "ensembl": "ENSG00000157404",
        "uniprot": "P10721",
        "omim": "164920"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "6342",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "3815",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000157404",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "164920",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P10721",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "158769",
          "disease_name": "Plaque-form urticaria pigmentosa",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "158766",
          "disease_name": "Typical urticaria pigmentosa",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "158778",
          "disease_name": "Isolated bone marrow mastocytosis",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "158775",
          "disease_name": "Smoldering systemic mastocytosis",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "158772",
          "disease_name": "Nodular urticaria pigmentosa",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "2884",
          "disease_name": "Piebaldism",
          "association_type": "Disease-causing germline mutation(s) (loss of function) in"
        },
        {
          "orphacode": "842",
          "disease_name": "Testicular seminomatous germ cell tumor",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "280785",
          "disease_name": "Bullous diffuse cutaneous mastocytosis",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "280794",
          "disease_name": "Pseudoxanthomatous diffuse cutaneous mastocytosis",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "566393",
          "disease_name": "Acute mast cell leukemia",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "566396",
          "disease_name": "Chronic mast cell leukemia",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "44890",
          "disease_name": "Gastrointestinal stromal tumor",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "90389",
          "disease_name": "Telangiectasia macularis eruptiva perstans",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "79455",
          "disease_name": "Cutaneous mastocytoma",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "98834",
          "disease_name": "Acute myeloblastic leukemia with maturation",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "98829",
          "disease_name": "Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)",
          "association_type": "Biomarker tested in"
        },
        {
          "orphacode": "98849",
          "disease_name": "Systemic mastocytosis with associated hematologic neoplasm",
          "association_type": "Disease-causing somatic mutation(s) in"
        },
        {
          "orphacode": "102724",
          "disease_name": "Acute myeloid leukemia with t(8;21)(q22;q22) translocation",
          "association_type": "Biomarker tested in"
        }
      ],
      "context": "ent groups. The interactive response technology assigned a randomisation number to the participant, which was used to link the participant to a treatment group and specified a unique medication number for the first package of study treatment dispensed to the participant as well as unique medication kit numbers for all study treatments dispensed at later visits. Randomisation was stratified by treatment with corticosteroids, mycophenolic acid, or both (yes or no) to ensure that the proportion of participants being treated with these agents was similar in the iptacopan and placebo treatment groups.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "ang",
      "hgnc_symbol": "ANG",
      "full_name": "angiogenin",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "483",
        "entrez": "283",
        "ensembl": "ENSG00000214274",
        "uniprot": "P03950",
        "omim": "105850"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "483",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "283",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000214274",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "105850",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P03950",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "803",
          "disease_name": "Amyotrophic lateral sclerosis",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "tment to post-treatment provides an ternative method of evaluating the benefit of iptacopan, though the pretreatment eGFR values are based nm historical creatinine values collecte fore study nrolment. The eGFR slope analysis by treatment group howed that the iptacopan group had stabilisation of the ang opLT eo © no\n\nContributors\n\nAll authors had access to the study data. DK, CMN, RKI, YW, IK, and IS have accessed and verified the patient-level study data. DK, ASB, MV, CMN, GR, M-HZ, EKSW, YW, IK, AJT, NJAW, MM, and RJHS were involved in the conceptualisation of the published work. YW, IK, and IS",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Proc",
      "hgnc_symbol": "PROC",
      "full_name": "protein C, inactivator of coagulation factors Va and VIIIa",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "9451",
        "entrez": "5624",
        "ensembl": "ENSG00000115718",
        "uniprot": "P04070",
        "omim": "612283"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "9451",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "5624",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000115718",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "612283",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P04070",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "745",
          "disease_name": "Severe hereditary thrombophilia due to congenital protein C deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol 2021; 8: 6344-54,\n\n15 Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci USA 2019; 116: 7926-31.\n\nData sharing\n\nNovartis provides access to the complete de-identified patient data set accompanied by a data dictionary following requests submitted via https: //clinicalstudydatarequest.com/Default.aspx. Data are available for request after European Medicines",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Gale",
      "hgnc_symbol": "GALE",
      "full_name": "UDP-galactose-4-epimerase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "4116",
        "entrez": "2582",
        "ensembl": "ENSG00000117308",
        "uniprot": "Q14376",
        "omim": "606953"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "4116",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "2582",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000117308",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "606953",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q14376",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "308487",
          "disease_name": "Generalized galactose epimerase deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "308473",
          "disease_name": "Erythrocyte galactose epimerase deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079-89.\n\n3 Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy— understanding a rare complement-driven renal disease. Nat Rev Nephrol 2019; 15: 129-43.\n\n26 Downward L, Wong K, Proudfoot C, Webb NJA, Wong E, Gale D. Patient characteristics and renal outcomes of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the UK: a retrospective analysis of 287 patients in the UK National Registry of Rare Kidney Diseases (RaDaR). J Am Soc Nephrol 2023; 34 (11S): S271-72.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "IgA",
      "hgnc_symbol": "CD79A",
      "full_name": "CD79a molecule",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "1698",
        "entrez": "973",
        "ensembl": "ENSG00000105369",
        "uniprot": "P11912",
        "omim": "112205"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "1698",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "973",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000105369",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "112205",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P11912",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "loop, thus preventing downstream generation of alternative pathway C5 convertase, C3a and C5a anaphylatoxins, and the membrane attack complex. Iptacopan is also approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria and for the reduction of proteinuria in adults with primary IgA nephropathy. In a phase 2 study, 12-week iptacopan treatment resulted in proteinuria reduction and stabilisation of estimated glomerular filtration rate (eGFR) in patients with C3 glomerulopathy. These effects persisted 9 months later, when assessed as part of the extension study. The improvements",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "SGLT2",
      "hgnc_symbol": "SLC5A2",
      "full_name": "solute carrier family 5 member 2",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "11037",
        "entrez": "6524",
        "ensembl": "ENSG00000140675",
        "uniprot": "P31639",
        "omim": "182381"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "11037",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "6524",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000140675",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "182381",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P31639",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "associated with substantial inhibition of the alternative pathway, thus confirming the mechanism of action of iptacopan.” In this study, we aimed to evaluate the efficacy, safety, and tolerability of iptacopan compared with placebo in\n\n(ie, <7-5 mg) corticosteroids, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists were allowed when stable for at least 90 days before randomisation. Demographic data on race (White, Black or African American, Asian, Chinese, Indian, Japanese, Korean, Vietnamese, Native Hawaiian or other Pacific Islander, American Indian, o",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "his",
      "hgnc_symbol": "HAL",
      "full_name": "histidine ammonia-lyase",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "4806",
        "entrez": "3034",
        "ensembl": "ENSG00000084110",
        "uniprot": "P42357",
        "omim": "609457"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "4806",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "3034",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000084110",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "609457",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P42357",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "Rizk DV, Maillard N, Julian BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy. Front Immunol 2019; 10: 504.\n\nreceived grants or contracts from Gyroscope Therapeutics, Kidney Research UK, Macular Society, Medical Research Council, and Wellcome Trust; and his spouse works for GSK. ASB has received consulting honoraria from Achillion, Alexion, Amgen, Apellis, Catalyst, GSK, Novartis, Otsuka, and Silence Therapeutics. MV has received honoraria for advisory boards and consulting fees and participated as Principal Investigator in clinical studies sponsored",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "ASB",
      "hgnc_symbol": "ALAS2",
      "full_name": "5'-aminolevulinate synthase 2",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "397",
        "entrez": "212",
        "ensembl": "ENSG00000158578",
        "uniprot": "P22557",
        "omim": "301300"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "397",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "212",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000158578",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "301300",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P22557",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "an BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy. Front Immunol 2019; 10: 504.\n\nreceived grants or contracts from Gyroscope Therapeutics, Kidney Research UK, Macular Society, Medical Research Council, and Wellcome Trust; and his spouse works for GSK. ASB has received consulting honoraria from Achillion, Alexion, Amgen, Apellis, Catalyst, GSK, Novartis, Otsuka, and Silence Therapeutics. MV has received honoraria for advisory boards and consulting fees and participated as Principal Investigator in clinical studies sponsored by the following pharmaceu",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    }
  ]
}